Carna Biosci in China distribution deal

Japan's Carna Biosciences has signed a distribution agreement with Shanghai Universal Biotech Co, under the terms of which SUBC will become the exclusive distributor of Carna's protein kinases within China.

With China's emergence as a strong market opportunity, particularly in the life sciences, major biopharmaceutical companies have now established research and production facilities in Shanghai and other regions of the country. These facilities seek and require goods to support their internal drug discovery programs. Carna is an established global provider of protein kinases used in the discovery and development of the class of drugs known as kinase inhibitors. The agreement with SUBC makes these products readily available to Chinese researchers via its strong distribution channels.

In addition to major biopharmaceutical presence, tax incentives provided by the Chinese government have created a fertile environment for the establishment of bio-venture companies and contract research organizations. The deal between Carna and SUBC, with its offices in the major cities of Shanghai and Beijing, is anticipated to lead to significantly-increased sales opportunities for Carna and further establish its reputation as a global provider of protein kinases.